IVF Affordability: Federal Actions to Lower Costs & Expand Access

The White House announced federal actions to lower IVF costs and expand access, including discounted medications via TrumpRx.gov starting 2026, faster FDA approvals for fertility drugs, and expanded employer fertility benefits. These steps aim to address financial barriers for the 1 in 6 people affected by infertility.

---

Key Takeaways

Lower Fertility Medication Costs via TrumpRx.gov

A new pricing agreement with EMD Serono will reduce out-of-pocket costs for IVF medications like Gonal-f and Pergoveris. Starting January 2026, patients can purchase these drugs directly from manufacturers through TrumpRx.gov, potentially saving thousands per cycle.

Faster FDA Approvals for Fertility Drugs

The FDA will fast-track approvals for new and combination fertility medications, including Pergoveris. This initiative aims to increase market competition and reduce drug prices by accelerating innovation and availability.

Expanded Employer Fertility Benefits

Federal guidance encourages employers to offer standalone fertility benefits similar to dental or vision coverage. This allows employers to design affordable fertility plans without altering primary medical insurance, improving employee access to care.

Addressing Rising IVF Medication Prices

Fertility drug prices have risen over 80% in the past decade, accounting for nearly one-third of IVF costs. The new policies target this financial barrier by negotiating lower prices and streamlining drug approvals to foster market competition.

Ensuring Equitable Access Through Policy Implementation

Experts emphasize that the success of these policies depends on transparent implementation and employer participation. The Fertility Providers Alliance advocates for patient-centered guidelines to ensure affordability and accessibility for all individuals seeking IVF treatment.

---

Source: Read full article